[{"id":"905333b0-c231-4b4c-9398-54fd991944d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04257110","created_at":"2021-01-18T20:41:30.309Z","updated_at":"2024-07-02T16:35:26.100Z","phase":"Phase 1","brief_title":"A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors","source_id_and_acronym":"NCT04257110","lead_sponsor":"Bliss Biopharmaceutical (Hangzhou) Co., Ltd","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BB-1701"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 208","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-12-15"}]